The FDA has approved Omidria (phenylephrine and ketorolac injection) 1%/0.3%, from Omeros Corp, for use during Cataract surgery or intraocular...
The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion for Omidria (phenylephrine and ketorolac injection)...
Omeros Corporation announced that it has entered into a definitive agreement for the sale of Omidria to Rayner Surgical Group Limited.
Omeros Corporation announced that the European Commission has granted marketing authorization for Omidria (phenylephrine 1% and ketorolac 0.3% injection) in...
Omeros Corporation announced the successful outcome of its recently completed post-marketing clinical trial of the effect of Omidria (phenylephrine and...
Omeros Corporation announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug Omidria (phenylephrine and ketorolac...
Omeros Corporation announced that the results of four real-world clinical studies evaluating the benefits of Omidria (phenylephrine and ketorolac intraocular...
Omidria is indicated in adults for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery.